Wire · opportunities
Adicet Bio Announces FDA Clearance of IND Application for ADI-212
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 28 August 2026 · Fusion42 review
The FDA has cleared Adicet Bio's IND application for ADI-212, a next-generation gene-edited CAR T cell therapy targeting metastatic castration-resistant prostate cancer. Phase 1 clinical trials are expected to begin enrollment in Q4 2026.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You have a new pathway open to trial a cutting-edge CAR T therapy using gene editing for prostate cancer, making the U.S. clinical market more accessible. Move quickly to engage with trial sites and regulatory consultants to position your therapy ahead of emerging competitors.
◆ Coverage
1 source · 28 Aug 2026
◆ Related on Wire
◆ Topics